Helge G. Bischoff
Expertise in
2
conditions

Helge G. Bischoff

Thoraxklinik Heidelberg
Heidelberg, BW, DE 
Expertise in
2
conditions
Thoraxklinik Heidelberg
Heidelberg, BW, DE 

Overview

Helge Bischoff practices practicing medicine in Heidelberg, Germany.

Mr. Bischoff is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

He is actively involved in clinical research, co-authoring 50 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Thoraxklinik Heidelberg
Heidelberg, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: March 04, 2026
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 3
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 3
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Enrollment Status: Completed
Publish Date: October 28, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 3 Less Clinical Trials

50 Total Publications

Chemoimmunotherapy Versus Chemotherapy for Extensive-Stage Small Cell Lung Cancer in the Real-World Setting: Retrospective Study of 904 Patients.
Chemoimmunotherapy Versus Chemotherapy for Extensive-Stage Small Cell Lung Cancer in the Real-World Setting: Retrospective Study of 904 Patients.
Journal: Clinical lung cancer
Published: April 05, 2026

Frequently Asked Questions about Helge G. Bischoff

Is Helge G. Bischoff a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Helge G. Bischoff is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Helge G. Bischoff participate in research or clinical trials?

Yes. Helge G. Bischoff has published 50 articles and abstracts on conditions like Lung Cancer. You can view a list of Helge G. Bischoff's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bischoff's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile